Skip to main content

vedolizumab (Entyvio®)

 

Status: In progress

Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children. 

  • Crohn's disease: following loss of response or non-response to anti-TNF and ustekinumab;
  • ulcerative colitis: following loss of response or non-response to anti-TNF treatment.

Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.

Medicine details

Medicine name vedolizumab (Entyvio®)
Formulation infusion
Reference number OW24
Indication

As above

Company Takeda UK Ltd
BNF chapter Gastro-intestinal system
Submission type One Wales
Status In progress
Date of issue TBA
Follow AWTTC: